Remix Therapeutics Inc., a Cambridge, Mass.-based startup developing small-molecule RNA modulators, said it has raised $65 million in series A financing led by Foresite Capital.
Rayzebio Inc. has swiftly followed up its recent $45 million series A round with a $105 million series B round that attracted several top-tier crossover investors.
HONG KONG – Olix Pharmaceuticals Inc. has raised ₩41.5 billion (US$37.90 million) to support the company’s U.S. expansion and advance its pipeline globally.
Genesis Therapeutics Inc. CEO and co-founder Evan Feinberg likens the collaboration of his company’s team of chemists, biologists and software developers to that of a jazz band. Everyone has to be familiar with everyone else’s roles and responsibilities in order to do their job, or play a solo, when it’s their turn.
RSS
